See today's BioWorld Asia
To read the full story, subscribe or sign in.

The trouble with TIGITs: Genentech’s failure sparks worry across class

May 17, 2022
By Lee Landenberger
A phase III failure for Roche Holding AG unit Genentech Inc.'s anti-TIGIT immunotherapy tiragolumab dragged down the share value of several other class entrants. 
BioWorld Asia Clinical Cancer